Targeted Medical Pharma, Inc. (TRGM) [Rocket]

Overview

Targeted Medical Pharma, Inc. (TRGM)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
05/17/2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/22/2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/18/2018	15-12G	Form 15-12G - Securities registration termination [Section 12(g)]:
12/12/2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/14/2016	10-K	Annual Report for the period ended December 31, 2015
03/31/2016	NT 10-K	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
03/08/2016	4	Wenkart Thomas Richard (10% Owner) has filed a Form 4 on Targeted Medical Pharma, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11	Dec-31-10	Oct-31-10	Dec-31-09
Revenues	5.3	7.1	9.6	7.3	8.8	7.6	0.0	12.2
Revenue growth	-26.0%	-25.6%	31.0%	-17.2%	15.6%	-37.5%		0.3%
Cost of goods sold	2.1	2.2	3.0	3.2	2.8	2.6	0.0	4.4
Gross profit	3.2	4.9	6.6	4.1	6.1	5.0	0.0	7.8
Gross margin	60.2%	68.8%	68.7%	56.1%	68.7%	66.3%		63.6%
Selling, general and administrative	5.2	7.3	10.2	10.1	11.7	6.3	0.0
Sales and marketing							0.0	0.2
Research and development	0.0	0.2	0.2	0.1	0.2	0.3		0.0
General and administrative							0.0	1.8
EBITA	-2.0	-2.3	-3.6	-5.9	-5.8	-1.6	0.0	2.2
EBITA margin	-37.8%	-32.9%	-37.4%	-80.7%	-65.6%	-20.7%		18.0%
Amortization of intangibles	0.2	0.3	0.3	0.2
EBIT	-2.2	-2.6	-3.8	-6.1	-5.8	-1.6	0.0	2.2
EBIT margin	-41.2%	-36.7%	-40.2%	-84.1%	-65.6%	-20.7%		18.0%
Pre-tax income	-3.1	-3.8	-3.7	-12.8	-6.6	-0.8	0.0	2.2
Income taxes	0.0	0.1	5.7	-3.2	-2.5	-0.3	0.0	-1.8
Tax rate	0.8%			24.9%	37.2%	39.6%
Net income	-3.0	-3.9	-9.3	-9.6	-4.2	-0.5	0.0	4.0
Net margin	-57.9%	-54.8%	-97.7%	-131.4%	-47.4%	-6.6%		32.6%

Diluted EPS	($0.11)	($0.15)	($0.39)	($0.43)	($0.19)	($0.03)	$0.00	$0.21
Shares outstanding (diluted)	27.2	26.4	23.8	22.2	21.9	18.5	5.0	18.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.